Shelley Boyd, MD, FRCSC, is an Ophthalmologist specializing in diseases of the retina. She was formerly Head of the Ocular Angiogenesis Research Program, global, with Novartis (Switzerland), overseeing translational aspects of the Ranibizumab program. She is Founder of Translatum Medicus inc and Tracery Ophthalmics, both selected as members of JLABS@Toronto. Tracery was awarded 1st place internationally for “Artificial Intelligence in Drug Development”, Dec 2017, from J&J. Shelley is Director of Canada’s only “High Risk Dry AMD Clinic”, St Michael’s Hospital, University of Toronto.